Drugs / Gallium-68 DOTATOC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02419664 | Jan 2015 → Jan 2022 | pituitary tumor | Göteborg University | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02375464 | Apr 2015 → Dec 2018 | neuroendocrine neoplasm | Northwell Health | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium-68 DOTATOC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02419664 ↗ |
| Modality | Diagnostic / imaging agent | “imaging agent” NCT02375464 ↗ |
| Route | Intravenous | “Route of administration: Intravenously” NCT02419664 ↗ |